Taken together these data provide the research community with empirical information for the safe and effective dosing of mice with STO-609 and highlight the utility of pharmacological inhibition of CaMKK2 signaling to attenuate NAFLD. Here, CAMKK2 is linked to metabolic dysfunction-associated steatotic liver disease.